Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01859299 · ClinicalTrials.gov registry record

Intestinal Bacteria and Ocular Inflammatory Disease

A clinical trial of Uveitis, sponsored by National Eye Institute (NEI).

Completed
Registry status
131
Enrollment target
1
Study location

NCT01859299: Completed study of Uveitis, sponsored by National Eye Institute (NEI).

NCT01859299 is a study of Uveitis that has completed, run by National Eye Institute (NEI). The registered enrollment target is 131 participants, below the 611-participant average among 19 other Uveitis trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01859299, a study of Uveitis, has completed, sponsored by National Eye Institute (NEI).

COMPLETED
Registry status
131 participants
Enrollment target
1
Study location

Study Summary

Background: \- Uveitis is a general term describing a group of inflammatory diseases of the eye. The causes of uveitis are not fully understood. Researchers want to look at bacteria in the body that might be related to the inflammation. They will study the natural bacteria present in the gut and intestines of people with and without uveitis to understand their potential role in these diseases. Objectives: \- To study the intestinal bacteria in people with and without uveitis or ocular inflammatory disease. Eligibility: * Individuals at least 18 years of age who have uveitis or ocular inflammatory disease. * Individuals at least 18 years of age without uveitis or ocular inflammatory disease to serve as healthy controls. Design: * Participants may have more than one study visit (approximately 2-4) to assess possible changes in microbiome composition associated with treatment or disease activity. * At each visit, participants will have a full eye examination, including vision and eye pressure tests. They will provide blood samples for testing. Participants will also be provided a stool collection kit to take home. The samples may be sent or brought back to the clinic. * Treatment will not be provided as part of this study.

Primary Outcome

The primary outcome is principal component analysis using the unweighted UniFrac distance metric of microbial composition; the significance between groups will be tested by the Adonis method (http://qiime.org/tutorials/category\_comparison.html).

Conditions Studied

Study Locations (1)

Maryland

  • National Institutes of Health Clinical Center - Bethesda

Trial Details

FieldValue
Enrollment Target 131 participants
Start Date 2013-08-27
National Eye Institute (NEI)

221 total trials

What the finished NCT01859299 record still lists

NCT01859299 is an observational study that tracks outcomes without assigning an intervention. The registered 131 participants enrollment target is mid-sized for trials with a published cap, below the 611-participant average among 19 other Uveitis trials with a reported enrollment target (79% lower).

The record links to 1 condition, with Uveitis appearing as the primary indexed condition, and to 0 interventions.

NCT01859299 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT01859299 about?

NCT01859299 is a clinical study titled "Intestinal Bacteria and Ocular Inflammatory Disease". Background: \- Uveitis is a general term describing a group of inflammatory diseases of the eye. The causes of uveitis are not fully understood. Researchers want to look at bacteria in the body that might be related to the inflammation. They will study the natural bacteria present in the gut and in...

What is the current status of trial NCT01859299?

This trial is currently completed. The enrollment target is 131 participants. The study started on 2013-08-27.

What conditions does trial NCT01859299 study?

This clinical trial studies the following conditions: Uveitis.

Who is sponsoring clinical trial NCT01859299?

This trial is sponsored by National Eye Institute (NEI), which has 221 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01859299 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Uveitis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01859299's enrollment target sits among peer trials

131 10th of 19 higher than 10 of 19 other Uveitis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Uveitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03051464 · 131 participants · Phase 2

    No Surgery Trial / Two Dose-escalation Strategies

  • NCT04301843 · 131 participants · Phase 2

    Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma

  • NCT04748549 · 131 participants · NA

    Intraoperative VR for Older Patients Undergoing TKA

  • NCT05951179 · 131 participants · Phase 2

    Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT01859299, the US trial registry maintained by the National Library of Medicine. NCT01859299 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.